...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Free
Due Dilligence

Resverlogix Publications and Posters

Also see NCBI PubMed list here: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22apabetalone%22+OR+%22RVX-208%22

Posted by: BearDownAZ on Jun 06, 2019 10:04AM
URL: https://www.resverlogix.com/science-and-programs/publications

Resverlogix Presentations and Events

Also see Potential 2019 event list here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/719444-2019-potential-events/messages/2236572#message

Posted by: BearDownAZ on Jun 06, 2019 10:02AM
URL: https://www.resverlogix.com/investors/presentations-and-events

Resverlogix News

Also check out the link library at: https://agoracom.com/ir/Resverlogix/links

Posted by: BearDownAZ on Jun 06, 2019 10:00AM
URL: https://www.resverlogix.com/investors/news
Resverlogix Corp. Links

Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial

Posted by: BearDownAZ on Aug 14, 2019 06:43AM
URL: https://www.sciencedirect.com/science/article/abs/pii/S0002870319301978

Zacks SCR 8/5/19: Targeting September Readout for BETonMACE

Posted by: BearDownAZ on Aug 05, 2019 11:53AM
URL: https://s1.q4cdn.com/460208960/files/New...Research_08052019_T.RVX_Vandermosten.pdf

Effects of the Epigenetic BET-Inhibitor Small Molecule Apabetalone on Cognition in Patients with Diabetes and Cardiovascular Disease - AAIC 2019 Poster

Posted by: BearDownAZ on Jul 20, 2019 08:29AM
URL: https://www.resverlogix.com/upload/media.../2019-07-08---aaic-poster-2019-final.pdf

Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension

Posted by: BearDownAZ on Jul 20, 2019 08:26AM
URL: https://www.atsjournals.org/doi/10.1164/rccm.201812-2275OC

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

Posted by: BearDownAZ on Jul 20, 2019 08:24AM
URL: https://clinicalepigeneticsjournal.biome...l.com/articles/10.1186/s13148-019-0696-z

Apabetalone, a Selective Bromodomain and Extra-Terminal (BET) Inhibitor, Reduces Serum FGF23 in Cardiovascular Disease and Chronic Kidney Disease Patients -ERA-EDTA 2019 poster

Posted by: BearDownAZ on Jun 14, 2019 09:15AM
URL: https://www.resverlogix.com/upload/media...40e7e22ce/era-edta-poster-2019-fgf23.pdf

Apabetalone (RVX-208) Attenuates an Inflammatory Milieu that Enhances Adhesion of Monocytes to Endothelial Cells in Type 2 Diabetes Mellitus with Cardiovascular Disease Patients - ADA 2019 Poster

Posted by: BearDownAZ on Jun 10, 2019 04:48PM
URL: https://www.resverlogix.com/upload/media...9-vi-bioinformatics-poster-v07-final.pdf

The Evolution of Apabetalone

Posted by: BearDownAZ on Jun 06, 2019 10:08AM
URL: https://agoracom.com/ir/Resverlogix/foru...ote-apabetalone/messages/2175507#message

The Evolution of Apabetalone, Redux

Posted by: BearDownAZ on Jun 06, 2019 10:06AM
URL: https://agoracom.com/ir/Resverlogix/foru...ote-apabetalone/messages/2229116#message

Resverlogix Publications and Posters

Also see NCBI PubMed list here: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22apabetalone%22+OR+%22RVX-208%22

Posted by: BearDownAZ on Jun 06, 2019 10:04AM
URL: https://www.resverlogix.com/science-and-programs/publications